ABSTRACT

OBJECTIVE: To review the pathophysiology of allergic asthma and information on the pharmacology, clinical efficacy, safety profile, and direct drug costs for omalizumab to provide a basis for a defined role of this agent in allergic asthma therapy in managed care organizations.

SUMMARY: Omalizumab is a monoclonal antibody targeting the high-affinity receptor binding site on human immunoglobulin E (IgE). When bound by omalizumab, IgE does not bind to basophils. As a result, degranulation is attenuated and allergic asthma symptoms are reduced. In asthma trials, omalizumab reduced inhaled corticosteroid and rescue medication requirements and improved asthma control and asthma quality of life in moderate-to-severe allergic asthmatics with disease poorly controlled by inhaled corticosteroids. Omalizumab has generally been well tolerated. However, injection site reactions occur in nearly 1 of every 2 patients, a problem that generally becomes less with continued dose administration. Severe injection site reactions are reported in 12% of patients. Other adverse events commonly reported in clinical trials include viral infections (23%), upper respiratory infections (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). Because the acquisition cost of omalizumab is high (generally $15,000 to $44,000 per patient per year, before contractual discounts), its use is cost-prohibitive in all but the most severe, poorly controlled allergic asthmatic patients. Hence, there is a clear need for new interventions to improve the care of asthma patients.

Omalizumab (Xolair), a monoclonal anti-immunoglobulin E (IgE) antibody, provides clinicians with an additional option for treating allergy-induced asthma. This review will provide a cost analysis of omalizumab to assist health plans in their decisions regarding the utility of this drug in select patient populations. Additionally, to provide the reader with a better understanding of the potential role for this product, the pathophysiology of allergic asthma will be reviewed, and relevant information on the pharmacology, clinical efficacy, and safety profile for omalizumab will be presented.

Pathophysiology of Allergic Asthma

Although not all cases of asthma are clearly attributable to atopy (the genetic tendency to develop the allergic diseases), it is accepted that atopy can play an etiologic role in its pathophysiology. Researchers who have reviewed this literature to calculate the weighted mean-population-attributable risk suggest that approximately 40% of asthma cases can be attributed to atopy. Additionally, atopy is one of the strongest predisposing factors for the development of asthma.

Discussion of the pathophysiology of allergic asthma begins with exposure of an allergen to antigen-presenting cells (macrophages, dendritic cells) that engulf the allergen, process it, and display the peptide epitope of the allergen on its cell surface for presentation to T and B lymphocytes. This is followed by direct interactions between T and B lymphocytes, which initiate B lymphocyte activation and subsequent allergen-specific IgE production (Figure 1). IgE binds to high-affinity receptors (FcεRI) on basophils and mast cells (basophil-like cells located in tissues). During subsequent antigen exposure, the antigen forms a link with multiple FcεRI-bound IgE molecules on basophils. This triggers degranulation of these cells, resulting in the release of preformed inflammatory mediators (histamine, tryptase) and the synthesis and release of newly generated mediators (prostaglandins, leukotrienes) and cytokines (tumor necrosis factor [TNF], interleukin [IL]-4, IL-5, IL-6). Released mediators initiate an early-phase response within minutes after allergen exposure. In the bronchial mucosa, this manifests as an asthma exacerbation.
(mucosal edema, mucous production, bronchial smooth muscle spasm). Some mediators released during the acute-phase response act as chemoattractants and promote the infiltration of mucosal surfaces with eosinophils. With subsequent release of eosinophil and newly generated basophil products, a second wave of allergic symptoms can be observed over the 6 to 12 hours following the early-phase response.

**Omalizumab Pharmacology**

Omalizumab is a monoclonal antihuman IgE antibody. Omalizumab binds free human IgE with a binding affinity higher than that observed between IgE and FcεRI (Figure 1); it does not bind to basophils or to IgE that is already bound to FcεRI. These binding characteristics allow omalizumab to neutralize IgE-mediated responses without causing basophil degranulation that could occur if omalizumab bound to basophils or if omalizumab cross-linked with basophil-bound IgE. Omalizumab also promotes FcεRI down-regulation on basophils because of the close direct correlation between free serum IgE and the number of FcεRIs expressed on basophils. As a result of these actions, the amount of basophil-bound IgE is reduced.

**Clinical Efficacy Trials**

Omalizumab has been evaluated in randomized, placebo-controlled, double-blinded clinical trials involving adolescents and adults with moderate-to-severe persistent allergic asthma (Table 1). Two of these trials were identically structured. Omalizumab doses were administered subcutaneously and standardized so that patients received an approximate dose of at least 0.016 mg/kg per IU of IgE/mL every 4 weeks. Smaller doses of 150 mg or 300 mg were administered every 4 weeks; with larger monthly requirements, 225 mg, 300 mg, or 375 mg doses were administered every 2 weeks. Prior to enrollment, all inhaled steroid doses were converted to inhaled beclomethasone dipropionate (BDP) titrated to previous asthma control. In addition to the inclusion criteria listed in Table 1, patients needed to have residual asthma symptoms during the 2 weeks prior to randomization despite treatment with moderate-dose or high-dose inhaled corticosteroids (ICSs). Patients received 16 weeks of placebo or omalizumab in addition to their ICS therapy (steroid-stable phase). Therapies were then continued for another 12 weeks while ICS therapy was tapered (steroid-reduction phase).

These studies enrolled 1,071 patients; the average baseline forced-flow-volume-in-1-second (FEV1) measurement was approximately 70% of what was predicted. There was a significant reduction in exacerbation frequency among omalizumab recipients during the steroid-stable and steroid-reduction phases of both trials when compared with placebo recipients (Table 1). Among the secondary end points, statistically significant differences were observed in favor of omalizumab treatment with regard to asthma symptom scores, beta-agonist rescue therapy use at most weekly intervals, FEV1 measurements at most weekly intervals, and the number of patients experiencing an exacerbation. These differences were observed despite more successful ICS tapering among omalizumab recipients, with patients being maintained on lower ICS doses or without any ICS requirements. These differences persisted in a 24-week double-blind extension phase in which patients continued their study treatment and the lowest effective BDP dose.

In 2 other trials, study inclusion criteria stipulated that only patients with baseline high-dose ICS requirements be enrolled, thus capturing a sample of patients considered to have severe persistent allergic asthma (based on the fact that they required high-dose ICS for symptom control). In a clinical trial structured similarly to those above (except that patients were converted to inhaled fluticasone at doses that provided disease control, the steroid-reduction phase was 16 weeks, and the primary end point was the percentage reduction in the fluticasone dose needed to maintain disease control). Holgate et al. enrolled 246 adult-adolescents with severe persistent allergic asthma (mean baseline FEV1 of 62.9% and 66% for omalizumab and placebo recipients, respectively). Although the number of exacerbation episodes per patient was similar in the omalizumab and placebo
In the most recently published trial, Humbert et al. evaluated 419 patients with severe persistent allergic asthma (mean baseline FEV₁ 61% and 61.6% for omalizumab and placebo recipients, respectively), continuing asthma symptoms despite high-dose ICS, and a history of 2 exacerbations requiring systemic steroids or 1 exacerbation requiring hospitalization/emergency department (ED) care over the year prior to enrollment. When added to the patient’s baseline asthma therapy (attempts to taper inhaled ICS were not driven by study protocol) for 28 weeks, the asthma exacerbation rate was significantly lower among omalizumab recipients (Table 1). Among secondary parameters evaluated, omalizumab recipients had statistically significant greater improvements (versus placebo) in their morning peak expiratory flow rate, % reduction of ICS doses, and % reduction of ICS doses. In addition, omalizumab recipients experienced 48 fewer asthma-related deterioration incidents (95% CI: 27.8-64.8%) compared with placebo recipients.

In summary, omalizumab has been shown to be effective in reducing asthma exacerbations and improving asthma control in patients with severe persistent allergic asthma. It is an important therapeutic option for patients who continue to experience asthma symptoms despite high-dose ICS treatment.
flow (PEF) readings, FEV₁ measurements, and asthma symptom scores. Additionally, omalizumab recipients experienced a significantly lower rate of severe exacerbations (PEF <60% of personal best, requiring systemic corticosteroids) and total acute care visit requirements (doctor visits, ED care, hospitalization). Based on their findings, the investigators reported that 3 patients needed to be treated for 1 year with omalizumab to avoid 1 severe exacerbation.

To better evaluate omalizumab utility in real-life clinical practice, Ayres et al., in a multicenter, open-labeled study, randomized 312 poorly controlled (defined as at least 1 ED visit or hospitalization or at least 1 course of oral corticosteroids for asthma over the prior year) adult and adolescent patients with moderate-to-severe persistent allergic asthma, to best standard care (BSC) plus omalizumab or BSC only. The model for BSC was the guideline published by the National Heart, Lung, and Blood Institute. Over 12 months, omalizumab recipients experienced fewer asthma-deterioration-related incidents per patient day (ADRs), defined as 2 or more lost work/school days, the need for an unscheduled physician or hospitalization/ED visit, or the need for treatment with systemic corticosteroids or antibiotics due to asthma (Table 1). Additionally, more omalizumab recipients remained ADRI-free and fewer experienced multiple ADRIs. There were also differences in types of ADRIs, with a smaller percentage of omalizumab recipients requiring systemic corticosteroids (51.8% vs. 65.2%, P = 0.037), an unscheduled physician visit (33.5% vs. 50.6%, P = 0.007), or >2 days time off from work or school (43.5% vs. 57.3%, P = 0.031). Statistically significant differences in favor of omalizumab were observed in the measurements of rescue medication use, morning FEV₁ measurements, asthma symptoms scores, and mean daily ICS requirements.

Asthma-Related Quality of Life and Perceptions of Treatment Efficacy

Because conventional clinical measures of asthma are not complete descriptions of the functional impairments or improvements experienced in clinical trials, investigators also included measures of quality-of-life and treatment-efficacy perceptions. Quality of life was evaluated via a validated Asthma Quality of Life (AQLQ) Questionnaire. Impressions of therapy effectiveness were evaluated by asking patients and investigators to rate treatment efficacy as excellent, good, moderate, poor, or worse.

In the trials reported by Soler et al. and Busse et al., overall AQLQ scores among omalizumab recipients showed significantly greater improvement (relative to baseline) during all 3 treatment phases. Additionally, in each phase, a significantly greater proportion of patients experienced a clinically relevant change in their overall AQLQ score; a significantly greater proportion also experienced a large improvement (quantitatively greater than a clinically relevant change). Similar improvements were reported in the trials evaluating patients with severe persistent allergic asthma.

Patients’ and investigators’ impressions of therapy effectiveness were consistent with AQLQ evaluations, lending validity to this simple assessment method. With assessments performed at the end of the steroid-reduction phases, ratings by patients and investigators were more likely to be good or excellent for the omalizumab recipients. The percentage of patients indicating that response was good or excellent among omalizumab and placebo recipients, respectively, was: Soler et al., 70% versus 40%, P <0.001; Busse et al., 60.6% versus 38.1%, P <0.001; Humbert et al., 64.3% versus 43.3%, P <0.001. Investigator responses were similar to those of patients.

Secondary Analyses of Clinical Trial Data

Bousquet and colleagues pooled data from 7 adult/adolescent trials of allergic asthma (5 discussed in this text, not included here because it enrolled patients with concomitant allergic asthma and perennial allergic rhinitis, and 1 currently unpublished) to assess the effect of omalizumab treatment on exacerbations in patients with severe persistent allergic asthma. Asthma severity was based on the Global Initiative for Asthma guidelines, which categorize severity based on clinical features and the intensity of the therapy required for symptom control. This pooled analysis of 4,308 patients showed a lower rate of exacerbations for omalizumab recipients (0.91 vs. 1.47 exacerbations per year, P <0.001; 38% reduction). Additionally, omalizumab recipients had rates of hospitalization that were 52% lower (P = 0.041), ED visits that were 61% lower (P = 0.013), and unscheduled doctor visits that were 43% lower (P <0.001). Although the number needed to treat is not reported by the investigators, there are sufficient data to calculate such values. Approximately 6 patients would have to be treated for 1 year to avoid 1 unscheduled doctor visit, 25 would have to be treated for 1 year to avoid 1 ED visit, and 32 would have to be treated for 1 year to avoid 1 hospital admission.

In another publication, Bousquet and colleagues pooled data from 2 of the adult/adolescent clinical trials of allergic asthma to identify the baseline patient characteristics that are predictive of response to omalizumab. Logistic regression analysis of the data from the steroid-stable phase of these trials revealed that the following characteristics were predictive of response: a history of emergency asthma treatment in the prior year, a baseline requirement for high doses (>800 mcg/d) of inhaled BDP, and a baseline FEV₁ of <65% of predicted (odds ratio for response with all 3 factors present was 4.20, 95% CI: 1.69-10.45). Baseline IgE concentrations were not predictive of response. Among patients showing a response to omalizumab at 16 weeks (the end of the steroid-stable phase), 61% had responded by 4 weeks, and 87% had responded by 12 weeks of therapy.

With the data from the steroid-stable phases of 3 adult-adolescent trials of allergic asthma, Holgate et al. performed
a meta-analysis to evaluate the impact of omalizumab on an annualized rate of all asthma exacerbation episodes (AEEs) and significant AEEs (sAEEs, an exacerbation requiring doubling of the ICS dose or use of systemic steroids) among patients who were at high risk of serious asthma-related morbidity and mortality.\textsuperscript{39} The investigators defined this population as those patients who had ever been intubated or who, within the year prior to enrollment, had visited an ED, required an overnight hospitalization, or needed intensive care unit admission for an asthma exacerbation. The rate of AEEs and sAEEs was lower with omalizumab treatment relative to placebo (rates were 53% and 55% lower, respectively; \(P\) values < 0.001). The absolute difference (in favor of omalizumab) in sAEE rates increased dramatically with baseline FEV\textsubscript{1} severity. Differences in the risk of sAEEs translated into the need to treat 5 patients with omalizumab to maintain 1 patient free of sAEEs for the period of study (average of 41.7 weeks for the 3 studies).

**Safety and Tolerability**

In the omalizumab package insert, the descriptions of reported adverse events and those considered to be drug related in allergic asthma trials indicate that such events have occurred with similar frequency in omalizumab and placebo (injection) recipients. Most reactions were mild to moderate in severity.\textsuperscript{40} The most commonly reported adverse events with omalizumab therapy were injection-site reactions (45%), viral infections (23%), upper respiratory infections (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). Injection-site reactions of any severity occurred in 45% of omalizumab recipients and 43% of placebo recipients. Reactions included bruising, redness, warmth, burning, stinging, itching, hive formation, pain, induration, mass formation, and inflammation. Most of these reactions occurred within 1 hour of injection, resolved within 8 days, and generally decreased in frequency with subsequent dosing. Severe injection-site reactions were reported in 12% of omalizumab and 9% of placebo recipients. The package insert provides neither a description of “severe injection-site reaction” nor data on the percentage of patients who stopped therapy due to such reactions.

Although 1 group of investigators has reported a greater frequency of headache (17.5% vs. 5.7%), cough (7.8% vs. 1.9%), and nausea (6.8% vs. 0.9%) with omalizumab therapy,\textsuperscript{40} in the published reports of the adult-adolescent allergic asthma trials, there was typically little difference between omalizumab and placebo recipients with regard to adverse-event reporting. The types of events reported are consistent with the product package insert.\textsuperscript{23,24} Local injection-site reactions were associated with 8.6% to 20.4% of omalizumab injections and 6.5% to 10.3% of placebo injections.\textsuperscript{23,25} In the trial by Soler et al.,\textsuperscript{23} bruising was the most common reaction reported by both omalizumab and placebo recipients; redness, warmth, and itching were more common among omalizumab recipients.\textsuperscript{21}

In studies that include descriptions of laboratory monitoring with omalizumab treatment, clinically significant changes in such values have not been observed.\textsuperscript{22,26,28} Although early animal studies raised concerns about omalizumab-induced thrombocytopenia,\textsuperscript{41} the product manufacturer reports that clinical trials have not revealed cases of sustained thrombocytopenia in patients with normal baseline platelet counts (data on file, Genentech, Inc.). Additionally, in a recent report of an open-labeled safety trial of 864 patients with moderate-to-severe asthma, platelet counts of <100,000/mm\textsuperscript{3} occurred in 4.8% of omalizumab recipients and 5.7% of control patients (standard therapy group); a 50% drop was observed in 0.86% and 0.71%, respectively.\textsuperscript{42} None of the patients had platelet counts of <75,000/mm\textsuperscript{3}, all reductions were isolated and transient, and there were no reports of bleeding. Despite the early concerns with thrombocytopenia, there are no warnings, black-box messages, or contraindications in the product package insert that suggest that baseline platelet counts must be evaluated prior to initiating therapy with omalizumab.

According to the product package insert, anaphylaxis was reported in 3 patients (incidence of < 0.1%). These reactions occurred within 2 hours of a first or subsequent omalizumab dose. Symptoms included urticaria and throat and/or tongue edema. Respiratory failure was not observed, and all patients survived.\textsuperscript{40} Although urticaria is described in patients involved in the discussed clinical trials, it was not described as a common adverse event.\textsuperscript{23,24,26} These reactions were typically mild or moderate in severity and usually resolved quickly with therapy discontinuation or despite continued therapy; the incidence of urticaria has been similar in omalizumab and placebo recipients.

In clinical trials of omalizumab, several investigators included analysis of the development of antiomalizumab antibodies. Such antibodies were not detected in any of these trials.\textsuperscript{23,24,27,28} In the product package insert, it is reported that low titers of antiomalizumab antibodies have been detected in 1 of 1,723 treated patients.\textsuperscript{49} Although omalizumab administration results in immune complex formation, investigators have not observed evidence of reactions that would be considered manifestations of complex precipitation or complement activation.\textsuperscript{27,28}

Among the warnings in the product package insert is mention of malignant neoplasms.\textsuperscript{49} Malignancies were observed in 20 of 4,127 (0.5%) omalizumab recipients and 5 of 2,236 (0.2%) placebo recipients involved in clinical studies. In 18 of these patients, the events occurred within 12 months of therapy initiation; approximately 60% were within 6 months. Several patients had a history of cancers, premalignant conditions, or other risk factors for development of a malignancy. Although it is hypothesized that the immune systems of atopic persons may be better able to identify and reject clones of malignant cells, a link between IgE and cancer has not been established.\textsuperscript{43,44} Nevertheless, since the majority of patients in clinical trials have had no more than a year’s exposure to omalizumab, the risk for
malignancy with more prolonged treatment needs to be studied, particularly in individuals who may be at higher risk for malignancies.

## Cost Analysis

### Asthma Prevalence and Severity

In the 2003 National Health Interview Survey of persons aged 18 years or older, an estimated 9.7% (20.6 million) reported that they have been diagnosed with asthma during their lifetime and 6.4% (13.6 million) reported that they still have asthma.45 Among children younger than 18 years, an estimated 12.5% (9 million) have had asthma diagnosed at some time in their lives, with the percentage increasing as age increases.46 Almost 6% of those surveyed (4 million) reported having had an asthma attack in the 12 months preceding the survey. Among U.S. high school students (grades 9 to 12) who participated in the 2003 National Youth Risk Behavior Survey, 18.9% have been diagnosed with asthma at some time in their lives; 16.1% reported that they still had a diagnosis of asthma.47

The 1998 Asthma in America Survey reported that the percentage of patients reporting symptoms consistent with mild, moderate, and severe persistent asthma was 39.8%, 22.1%, and 19.1%, respectively, and 19.1% reported symptoms consistent with mild intermittent disease. In a more recent survey of pediatric asthmatics, the percentage of parents reporting that their child had symptoms consistent with mild, moderate, and severe persistent asthma over the 4 weeks prior to the interview was 14% in each category. The remainder of the respondents (58%) said their child had mild intermittent asthma.48

### Costs of Asthma

Recent economic analyses indicate that direct medical costs, particularly hospitalizations and medications, currently account for the largest component of asthma-related costs in the United States. Using data from surveys conducted by the National Center for Health Statistics, Weiss and colleagues examined the changes in asthma costs during the 10-year period from 1985 through 1994.1 The total cost of asthma was $10.7 billion in 1994, a figure that was more than twice the estimated cost of asthma (nearly $4.5 billion) 10 years earlier in 1984. This represented a 54.1% increase after adjustment to 1994 dollars. Direct medical costs (including charges for hospital inpatient and outpatient services, ED services, physician services, and medications) amounted to $6.10 billion in 1994 (56.8% of the total costs), an increase of 22.6% during the 10-year period. In 1985, hospital inpatient care represented the largest direct medical component cost (44.6% of total direct costs). In 1994, the largest component cost of asthma was medications ($2.45 billion, 40.1% of total direct costs), followed by hospital inpatient care ($1.80 billion, 29.5% of total direct costs). The authors indicated that these observed trends were the result of a decrease in length of hospital stay (rather than a decrease in hospitalizations) and an increase in both the total number of prescribed medications and the average unit cost per medication. Indirect costs (including the value of time lost from school and work, and mortality as measured by lifetime earnings) of asthma in 1994 were estimated at $4.6 billion (43.2% of the total costs). The largest component of indirect cost in 1994 was loss of work, which was estimated at $2.07 billion (44.6% of indirect costs). Table 2 presents the distribution of asthma costs in 1985 and 1994.

Cisternas and colleagues conducted a comprehensive study of the direct and indirect costs of adult asthma using data derived from a group of community physicians treating 401 adult asthma sufferers in the northern California area.49 In this study, annual asthma costs averaged $4,912 per person. Direct medical and nonmedical costs accounted for 64.8% of these costs. Fifty percent of direct total costs were ascribed to pharmaceuticals and only 14.6% to hospitalizations. Indirect costs (including wage losses associated with work disability and other productivity losses attributed to asthma disability in persons who did not work outside of home) accounted for 35.2% of total costs. Almost all of the indirect costs were attributed to work/productivity losses.

### Asthma Severity and Health Care Resource Utilization

In 2002, asthma accounted for 12.7 million doctor visits, 1.2 million hospital outpatient visits, 1.9 million ED visits, and 484,000 hospitalizations. Of these numbers, children aged 0 to 17 years had 5 million doctor visits, 727,000 ED visits, and 196,000 hospitalizations.50 A disproportionate amount of these health care resources is utilized by a relatively small cohort of patients with difficult-to-treat asthma.51-54 Some investigators have reported that as much as 80% of direct asthma costs are consumed by less than 20% of asthma patients (defined as

### Table 2: Distribution of Asthma Costs

<table>
<thead>
<tr>
<th>Cost Category</th>
<th>1985†</th>
<th>1994†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cost ($, billions)</td>
<td>~4.5</td>
<td>~10.7</td>
</tr>
<tr>
<td>Direct costs†</td>
<td>53.2%</td>
<td>56.8%</td>
</tr>
<tr>
<td>Medications‡</td>
<td>30%</td>
<td>40.1%</td>
</tr>
<tr>
<td>Hospital inpatient care‡</td>
<td>44.6%</td>
<td>29.9%</td>
</tr>
<tr>
<td>Physician services‡</td>
<td>11.6%</td>
<td>12.2%</td>
</tr>
<tr>
<td>Hospital outpatient care‡</td>
<td>5.4%</td>
<td>10.4%</td>
</tr>
<tr>
<td>Emergency department care‡</td>
<td>8.4%</td>
<td>7.8%</td>
</tr>
<tr>
<td>Indirect costs†</td>
<td>46.8%</td>
<td>43.2%</td>
</tr>
<tr>
<td>Work lost§</td>
<td>33%</td>
<td>44.6%</td>
</tr>
</tbody>
</table>

* Expressed in 1985 dollars; the 1994 equivalent was estimated to be approximately $7 billion.
† Expressed as a percentage of total cost.
‡ Expressed as a percentage of direct costs.
§ Expressed as a percentage of indirect costs.
Resource Use and Costs for Omalizumab Treatment:

A Health Plan’s Perspective

Drug Product Costs

According to package insert dosing guidelines, omalizumab is administered only by subcutaneous injection.60 Doses are standardized so that patients receive an approximate dose of at least 0.016 mg/kg per IU of IgE/mL every 4 weeks. Smaller doses of 150 mg or 300 mg are administered every 4 weeks; with larger dose requirements (225 mg, 300 mg, or 375 mg every 4 weeks), doses are divided and administered every 2 weeks. Because of the viscosity of the product, doses greater than 150 mg must be administered as separate injections. The 2005 average wholesale price for one 150-mg single-dose vial of omalizumab is $568.31.58 As shown in Table 3, the lowest dose regimen (one 150-mg vial every 4 weeks) will cost $7,388 per year ($616 per month), while the largest dose regimen (375 mg, or 3 vials, every 2 weeks) will cost $44,328 per year ($3,694 per month). Dose requirements for the majority of patients will be likely be >150 mg every 4 weeks since this regimen is used only for patients who are ≤90 kg and have serum IgE levels at the lowest end of the range (30-100 IU/mL).58 Therefore, an average omalizumab dose may be 300 mg every 4 weeks or 225 mg every 2 weeks, depending on the patient’s body weight.

TABLE 3  Annual Drug Cost for Omalizumab*†

<table>
<thead>
<tr>
<th>Dose Regimen</th>
<th>Vials per Dose</th>
<th>Injections per Dose†</th>
<th>Drug Cost ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>150 mg every 4 weeks</td>
<td>1</td>
<td>1</td>
<td>7,388</td>
</tr>
<tr>
<td>200 mg every 4 weeks</td>
<td>2</td>
<td>2</td>
<td>14,776</td>
</tr>
<tr>
<td>225 mg every 2 weeks</td>
<td>2</td>
<td>2</td>
<td>29,552</td>
</tr>
<tr>
<td>300 mg every 2 weeks</td>
<td>2</td>
<td>2</td>
<td>29,552</td>
</tr>
<tr>
<td>375 mg every 2 weeks</td>
<td>3</td>
<td>3</td>
<td>44,328</td>
</tr>
</tbody>
</table>

* Based on average wholesale price (2005) of $568.31 per 150 mg in a 1.2 mL vial (from reference 58). Also available in a 0.6 mL, 75 mg vial.
† Dose requirements for the majority of patients will likely be >150 mg every 4 weeks since this regimen is used only for patients who are ≤90 kg and have serum IgE levels at the lowest end of the range (30-100 IU/mL). In clinical trials of omalizumab, the mean serum IgE concentrations were 167-267 IU/mL.23-26,29 Therefore, an average omalizumab dose may be 300 mg every 4 weeks or 225 mg every 2 weeks, depending on the patient’s body weight.

Drug Acquistion, Preparation, and Administration-related Costs

Omalizumab distribution is restricted through a group of 5 specialty pharmacies, which can assist health care providers and patients with assessing insurance coverage and pursuing appropriate reimbursement authorization (i.e., obtaining prior approval). In order for specialty pharmacies to seek prior authorization from payers, the following information is requested: patient weight; International Classification of Diseases, Ninth Revision, (ICD-9) codes; current asthma therapies; documentation of a positive skin or radioallergosorbent test to a perennial aeroallergen; a statement of medical justification for omalizumab treatment; and a pretreatment IgE serum level (see http://www.xolair.com/hcp/hcp_home.jsp). Although the health care provider can obtain payer approval themselves, the drug would still need to be obtained through one of the specialty pharmacies. Under this circumstance, however, providers would need to forward prior authorization documentation to the specialty pharmacy or purchase the drug and bill the payer themselves. The drug may be shipped to the provider or directly to the patient. The time spent in this drug acquisition process is a factor to consider when the total cost of therapy is being evaluated.
Doses and dosing frequency of omalizumab are based on patient weight and baseline serum IgE levels. Measuring a serum total IgE level (IU/mL) before the start of treatment adds to the total costs of therapy. Since the single-use product vials contain no preservatives, the solution must be administered within 4 to 8 hours of reconstitution, depending on storage conditions. This requires additional planning on the part of the provider. As the lyophilized product takes approximately 15 to 20 minutes to dissolve, the patient must typically arrive at least 30 minutes before drug administration. Because of the product's cost, the patient's arrival is likely to be used as the trigger for the drug preparation and reconstitution process so as to prevent unnecessary waste. It is recommended that the patient also stay 30 minutes before drug administration. Because of the product's moderate-to-severe allergic asthma. Direct costs were considered (including unscheduled physician office visits, hospitalizations, ED visits, treatment costs for drug-related adverse events, and asthma medication treatment costs). All costs were reported in 2003 dollars; at the time of analysis, the wholesale acquisition cost for omalizumab was $433 for one 150 mg vial. The authors estimated that the average daily treatment cost for patients treated with omalizumab was $39.85 per patient compared with $2.08 for patients receiving placebo injections, with the significant difference between the 2 treatments due primarily to drug product cost. The average daily cost associated with utilization of other health care resources was $0.08 and $0.36 per patient for the omalizumab and placebo recipients, respectively. The cost of gaining 1 additional successfully controlled day with the use of omalizumab was $523. In the opinion of the authors, omalizumab use could result in cost savings only if used in the patient who is hospitalized at least 5 times or 20 days per year or requires at least 5. Observing the patient after subcutaneous injection for 1 to 2 hours for possible severe hypersensitivity reactions including anaphylaxis.

### Table 4: Ancillary Cost Considerations for Acquisition and Administration of Omalizumab

<table>
<thead>
<tr>
<th>Cost Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Measuring a patient's serum total IgE (IU/mL) before the start of treatment.</td>
</tr>
<tr>
<td>2.</td>
<td>Preparing paperwork necessary for drug acquisition.</td>
</tr>
<tr>
<td>3.</td>
<td>Reconstituting/preparing the lyophilized product (for each 150 mg vial):</td>
</tr>
<tr>
<td></td>
<td>• 15 to 20 minutes; the vial has to be shaken for 5 to 10 seconds approximately every 5 minutes to dissolve the solid particles; reconstituted product must be used within 4 to 8 hours, depending upon storage conditions.</td>
</tr>
<tr>
<td>4.</td>
<td>Injecting the product subcutaneously (no more than 150 mg injected per site).</td>
</tr>
<tr>
<td>5.</td>
<td>Observing the patient after subcutaneous injection for 1 to 2 hours for possible severe hypersensitivity reactions including anaphylaxis:</td>
</tr>
<tr>
<td></td>
<td>• medications (e.g., diphenhydramine, hydroxyzine, epinephrine) for the treatment of severe hypersensitivity reactions.</td>
</tr>
<tr>
<td>6.</td>
<td>Health care professional fees to perform the above tasks.</td>
</tr>
<tr>
<td>7.</td>
<td>Patient and family costs associated with time and travel every 2 to 4 weeks.</td>
</tr>
</tbody>
</table>

* It's likely that a majority of patients will require doses >150 mg since the regimen of 150 mg every 4 weeks is used only for patients who are ≤90 kg and have serum IgE levels at the lowest end of the range (30-100 IU/mL).
7 monthly ED visits for treatment of asthma-related events. Hence, these and other authors recommend that its use be restricted for moderate-to-severe allergic asthma in patients who are suboptimally controlled and require regular use of intensive health care resources for management of exacerbations. 5,23-29, 36, 38-40, 61-63 Although other authors have questioned the validity of the outcome measures utilized by Oba and Salzman, even such critics agree that omalizumab use is cost prohibitive in most patients. Miller and Reeves calculated an incremental cost-effectiveness ratio of $88,837 to prevent 1 unscheduled office visit for omalizumab versus placebo, $577,812 to prevent 1 hospitalization, or $755,600 to prevent 1 ED visit. 64

## Conclusion

Omalizumab is a subcutaneously administered monoclonal anti-IgE antibody that reduces free IgE concentrations and promotes down-regulation of IgE receptors on basophils. In patients with allergic asthma poorly controlled with inhaled steroids, omalizumab improves asthma symptom control and allows patients to be managed with lower inhaled steroid doses. Omalizumab has been well tolerated in clinical trials that have extended as long as 52 weeks. Almost half of patients experience injection-site reactions with omalizumab, and while these tend to decrease in frequency with subsequent dose administration, severe injection-site reactions occur in approximately 1 in 8 patients. Because omalizumab is much more expensive than standard asthma therapies, its use needs to be restricted to the most severe, poorly controlled allergic asthmatics who require frequent use of emergency care for exacerbations.

**DISCLOSURES**

No outside funding supported this study. The authors disclose no potential bias or conflict of interest relating to this article. Author Paul P. Belliveau served as

---

**TABLE 5  Proposed Criteria for Omalizumab Use**

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Comment</th>
<th>Reference, Criteria Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients should fulfill all of the following:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High-risk* patient with severe persistent asthma†</td>
<td>Indicated for moderate-to-severe asthma but product cost may dictate stricter criteria</td>
<td>23-29, 36, 38-40, 61</td>
</tr>
<tr>
<td>Age &gt;12 years</td>
<td>Labeled indication</td>
<td>40</td>
</tr>
<tr>
<td>Symptoms with appropriate therapy after 1-2 month trial</td>
<td>Appropriate maximal maintenance therapy for severe persistent asthma: high-dose ICS (&gt;800 mcg/day BDP, CFC or equivalent) plus LABA plus oral corticosteroid†</td>
<td>30, 37, 38, 40</td>
</tr>
<tr>
<td>Allergic triggers and environmental controls have been addressed</td>
<td>Evaluation by an allergy/immunology specialist might be considered to address these issues</td>
<td>30, 37</td>
</tr>
<tr>
<td>Patient inhaler technique, education, and adherence has been maximized§</td>
<td>Guidelines consider patient education and compliance key components of establishing disease control</td>
<td>30, 37</td>
</tr>
<tr>
<td>Serum IgE 30-700 IU/mL</td>
<td>Required to help establish that the patient has allergic asthma; dosing per the product labeling does not give guidance for IgE concentrations outside of this range</td>
<td>40</td>
</tr>
<tr>
<td>Body weight 30-150 kg</td>
<td>Dosing per the product labeling does not give guidance for patient weights outside of this range</td>
<td>40</td>
</tr>
<tr>
<td>Positive skin-prick testing or RAST</td>
<td>Per the product labeling, required to help establish that the patient has allergic asthma</td>
<td>40</td>
</tr>
</tbody>
</table>

* High-risk patients: those patients with a recent history (within the prior year) of frequent intubations, emergency room visits, overnight hospitalizations, intensive care unit admissions for asthma exacerbations.

† The severity of asthma may be classified by the frequency of symptoms and pulmonary function assessments prior to starting asthma therapy. However, since the criteria presented here apply to treatment-experienced patients, patients may be considered to have severe persistent disease if they require therapy consistent with this degree of disease despite not fulfilling the symptom frequency or pulmonary function requirements for severe persistent asthma. A low FEV1 (particularly ≤65%) is more predictive of response than higher FEV1 values at treatment initiation.

‡ If a patient requires chronic corticosteroid maintenance therapy for symptom management (i.e., corticosteroid-dependent asthma), omalizumab may be considered to reduce the exposure and long-term risks of this therapy even if such therapy provides adequate control.

§ If adherence and/or inhaler technique cannot be maintained despite documented adequate training and education, omalizumab may be considered if all other criteria are fulfilled.

BDP CFC = beclomethasone dipropionate, chlorofluorocarbon-containing; ICS = inhaled corticosteroid; LABA = long-acting beta-agonist; RAST = radioallergosorbent test.
Evaluation of Omalizumab From a Health Plan Perspective

principal author of the study. Study concept and design, data collection, and analysis and interpretation of data were contributed primarily by Belliveau, with input from author Monina R. Lahoz. Drafting of the manuscript was primarily the work of Belliveau, and its critical revision was the work of both authors.

REFERENCES


